StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
NASDAQ:AKTX opened at $3.32 on Friday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $4.40. The stock’s fifty day moving average is $3.58 and its two-hundred day moving average is $2.51.
Akari Therapeutics Company Profile
Read More
- Five stocks we like better than Akari Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Investing in Travel Stocks Benefits
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- What is the Dow Jones Industrial Average (DJIA)?
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.